Novacyt S.A.
("Novacyt", the "Company" or the
"Group")
Result of AGM
Paris, France, and Eastleigh and Manchester,
UK - 18 July 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM:
NCYT), an international molecular diagnostics company with a broad
portfolio of integrated technologies and services, announces that
all resolutions proposed at the ordinary general meeting part of
the Company's Annual General Meeting (AGM), held today, were duly
passed.
As part
of the AGM, the Company also met today to hold an extraordinary
general meeting. The meeting was not deemed quorate due to the
minimum number of voting rights under French company law not being
present or represented at the meeting. Consequently, the meeting
did not take place.
Following the AGM,
Steve Gibson and Joanne Mason have now formally joined the Novacyt
Board, as Executive Directors.
The
results of the AGM voting will be made available on the Company's
website.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn
Rees, Chief Executive Officer
|
Via Walbrook PR
|
|
Steve
Gibson, Chief Financial Officer
|
|
|
SP Angel Corporate Finance LLP
(Nominated Adviser and Broker)
|
+44 (0)20 3470 0470
|
|
Matthew
Johnson / Charlie Bouverat (Corporate Finance)
Vadim
Alexandre / Rob Rees (Corporate Broking)
|
|
|
|
|
|
Deutsche Numis
(Joint Broker)
|
+44 (0)20 7260 1000
|
|
Freddie
Barnfield / Duncan Monteith / Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing
Sponsor)
Rémi
Durgetto / Yannick Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR (Financial PR &
IR)
Stephanie Cuthbert / Paul McManus
/
Phillip
Marriage / Alice Woodings
|
+44 (0)20 7933 8780 or novacyt@walbrookpr.com
+44 (0)7796 794 663 / +44 (0)7980 541
893
+44 (0)7867 984 082 / +44 (0)7407 804
654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The
Company develops, manufactures, and
commercialises a range of molecular assays
and instrumentation to deliver workflows and services that enable
seamless end-to-end solutions from sample to result across multiple
sectors including human health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical
in vitro diagnostic
products, workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size
selection DNA sample preparation platforms and rapid
PCR machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
·
MyGo: real-time quantitative PCR (qPCR)
instruments
|
|
Research Use Only
|
Range of services for the life
sciences industry:
·
Design, manufacture, and supply of
high-performance qPCR assays and workflows for use in human health,
agriculture, veterinary and environmental, to support global health
organisations and the research industry
·
Pharmaceutical research services: whole genome
sequencing (WGS) / whole exome sequencing (WES)
|
Novacyt is headquartered in
Vélizy-Villacoublay in France with offices in the UK (in Stokesley,
Eastleigh and Manchester), Taipei, Singapore, the US and Canada and
has a commercial presence in over 65 countries. The Company is
listed on the London Stock Exchange's AIM market ("NCYT") and on
the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com